Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2071 to 2085 of 8933 results

  1. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-IPG10392 Expected publication date: TBC

    Interventional procedures guidance
    In development

  2. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Seladelpar for previously treated primary biliary cholangitis [ID6429]

    In development Reference number: GID-TA11540 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Severe and enduring mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  5. Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

    In development Reference number: GID-TA11772 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  6. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  8. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development Reference number: GID-TA11454 Expected publication date:  23 July 2026

    Technology appraisal guidance
    In development

  9. Filgotinib for treating axial spondyloarthritis [ID6594]

    In development Reference number: GID-TA11776 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]

    In development Reference number: GID-TA10223 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]

    In development Reference number: GID-TA11802 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (review of TA901) [ID6610]

    In development Reference number: GID-TA11850 Expected publication date:  03 September 2026

    Technology appraisal guidance
    In development

  14. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

    In development Reference number: GID-NG10469 Expected publication date: TBC

    NICE guideline
    In development